Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib.

ABSTRACT:

SUBMITTER: Dewulf J 

PROVIDER: S-EPMC12817464 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature